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Metabolic Disorders in Patients 
with Chronic Osteomyelitis: 
Etiology and Pathogenesis
Archil Tsiskarashvili, Nikolay Zagorodny, 
Svetlana Rodionova and Dmitry Gorbatyuk
Abstract
In this study, we discuss the peculiarities of metabolic disorders that follow the 
development of chronic osteomyelitis. For the purposes of this study, we analyzed 
the available data as well as results of our own clinical and scientific research. 
Chronic osteomyelitis leads not only to the destruction of bone tissue by pathogen 
but also to the shift of equilibrium between osteogenesis and bone resorption in the 
locus of bone infections. Such shift leads to additional damage not only to the bone 
cells (primarily osteoblasts) but also to the bone matrix. The final complications 
include difficulties with bone consolidation and prolongation of therapy, even when 
the patient is treated using an external fixation method like Ilizarov or similar tech-
niques. Etiopathogenetic therapy, aimed at correction of metabolic disorders, allows 
to shorten the bone consolidation time (and respectively, the treatment time), 
preventing different pathogenetic processes that exacerbate and enhance each 
other’s effects. This study emphasizes the importance of etiopathogenetic therapy 
of metabolic disorders in patients with chronic osteomyelitis. Etiopathogenetic 
therapy should be combined with other necessary methods of the patient’s treat-
ment, such as surgical debridement of the infection locus and antibiotic therapy.
Keywords: chronic osteomyelitis, metabolic disorders, bone tissue
1. Introduction
The empirical experience of surgeons operating patients with orthopedic 
infection shows that the mechanical properties of the bone (including strength) 
differ from physiological ones. The bone in or near the infected area tends to be 
more fragile and soft. Proper mechanical strength of the bone tissue is one of the 
key factors for completing successful osteosynthesis as the mechanical strength of 
the bone directly influences the stability of fixators, treatment of bone tissues in the 
surgery process, and other technical but pivotal aspects of the treatment.
Despite some empirical data, the change of mechanical properties of the bone in 
orthopedic infection remained practically unresearched for a long time. The change 
of the mechanical properties of the bone in inflamed areas had been connected to 
tissue destruction or lysis caused by bacterial pathogen. In other words, this change 
of the mechanical properties of the bone happening in the inflamed area was 
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viewed similarly as the complications in soft tissues in the purulent surgery, widely 
known for a long period of time.
Consequently, this falsely simplified view of the problem has led to a shortage of 
publications. For example, the search query in the PubMed database based on Mesh 
terms “Osteomyelitis” and “Bone mineral density” (latest access time: December 
08, 2019, 0:01 UTC +3) has provided only 30 search results, the earliest of them 
is signed as published in February 1991. Most publications refer to dentistry and 
maxillofacial surgery but not to traumatology and/or orthopedics. Another search 
based on Mesh terms “Osteomyelitis” and “Metabolic disorders” (latest access time: 
December 08, 2019, 0:03 UTC +3) has provided 596 results, but most papers refer 
to other topics and problems: “combinations” of chronic osteomyelitis and diabetes 
mellitus [1, 2], chronic osteomyelitis and bisphosphonate-induced necrosis of 
the jaw [3, 4]; less papers refer to the problem of treating chronic osteomyelitis in 
patients with genetic, systemic, neuropathic, and oncological diseases [5–8]. In sev-
eral papers, the accent is put on the clinical aspects of bone infection with particular 
pathogens only [9–11]. Some papers can be considered of a relatively good quality 
but the accent is put on clinical results themselves and not on the pathogenesis of 
metabolic bone tissue disorders in the presence of bone infection [12, 13].
Numerous clinical guidelines and publications on osteoporosis and related 
disorders have much to offer about the pathophysiology of these diseases, but have 
a rather serious common disadvantage: they do not describe or poorly describe the 
interaction of pathogen and bone tissue, although the infectious and purely osteo-
porotic metabolic processes have similar mechanisms.
Lack of understanding of the metabolic bone tissue disorders as a result of its 
interaction with bacterial pathogen during orthopedic infection practically elimi-
nated the possibility of providing adequate etiological treatment; in most cases, the 
treatment methods were limited to surgical treatment (necrectomy, debridement, 
external fixation, and related methods) and antibiotic therapy. Despite being 
approved and reliable, these methods themselves are not enough to treat chronic 
osteomyelitis. The correction of the impaired bone tissue metabolism is also needed. 
For this purpose, a clinician should be familiar with the aspects of biochemistry, 
physiology, and pathophysiology of the bone affected by orthopedic infections.
At this moment, several fundamental papers in the domain of bone tissue and 
pathogen interaction are available [14, 15], which can be evaluated as a positive 
trend. These works can be useful to systematize the knowledge cumulated by the 
scientific community.
Within this chapter, we made an attempt to synergize the knowledge in 
pathophysiology of the disorders described, as well as illustrate the importance of 
correction of impaired bone tissue metabolism using the results of our own work 
published in 2019 [16].
2.  Pathogenesis of metabolic bone tissue disorders at the site of 
orthopedic infection
Current views on chronic osteomyelitis allow its understanding not simply as a 
“bone-lytic” or “infectious” process, but also as a condition associated with bone 
metabolism alteration. Understanding the nature of these alterations is one of 
the key points in treating chronic osteomyelitis. Without this understanding, the 
process of treatment may not succeed or may be less successful even if supported by 
superb surgery and antibiotic therapy (Figure 1).
As an attempt to describe the links between changes in bone tissue metabolism dur-
ing orthopedic infection, we created a scheme displayed above. From our point of view, 
deep understanding of the pathogenesis is of paramount importance for a clinician.
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The overall scheme can be divided into three major parts, which represent main 
pathogenetic pathways enforcing and exacerbating each other while developing at 
the same time:
1. Osteoblast cell death and proliferation lowering.
2. Bone remodeling shift to the resorption prevalence.
3. Matrix destruction.
These parts will be discussed separately to make them easier for understanding, 
even though the pathogenic processes described would influence each other in a 
“crossing-over” manner. De facto, it is hardly possible to separate them because all 
of the components take part in general bone metabolism and remodeling process.
The color of the blocks is associated with their aim:
• Blue blocks represent the stages of pathophysiological processes.
• Red blocks represent the “final” changes in the levels of the markers (e.g., beta-
cross-laps (C-terminal telopeptide) increase). These changes can be detected 
using laboratory methods and are used by a clinician during the diagnostics.
• Yellow blocks represent the background factors (markers and their levels) that 
also can be measured with methods of laboratory diagnostics.
Figure 1. 
Pathogenesis of metabolic disorders of the bone tissue, influence of the background factors and laboratory 
diagnostic markers (figure credits: Gorbatyuk D.S., Tsiskarashvili A.V., Rodionova S.S.).
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3. Osteoblast cell death and proliferation lowering
One of the most obvious effects of bacterial pathogen on a bone tissue is the 
destruction of osteoblasts.
Destruction of osteoblasts includes necrotic and apoptotic pathways. Papers 
contributing to the study of S. aureus’ influence on the osteoblast culture show that 
these two pathways work independently. Apoptosis is triggered by ligand TRAIL 
Figure 2. 
Pathogenetic stages and processes associated particularly with osteoblast cell death and proliferation lowering. 
The link between bone matrix destruction processes and associated decrease in osteoblast proliferation rate (will 
be shown and illustrated in the corresponding part of the chapter).
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linking with “death receptors” DR4 and DR5, and necrosis is triggered by S. aureus 
toxins PSMα и PSMβ that destroy the osteoblast cell membrane [15, 17, 18].
Lowering of the osteoblast number leads to slowing of ossification and mineral-
ization of the bone. The level of bone resorption can remain stable or be increased 
at the same time (see “Bone remodeling shift”).
As a result, the production of bone alkaline phosphatase lowers [15]. We must 
say that alkaline phosphatase itself is not very convenient as a marker: it is produced 
by different cell types in four different forms. In this case, we have an interest in 
bone alkaline phosphatase that is coded with ALPL gene [19]. For precise diag-
nostics, a laboratory should have a specially trained personnel and corresponding 
equipment. A clinician should note that children and adolescents have normally 
elevated levels of bone alkaline phosphatase in comparison to adults, and the 
association between age and serum level of BAP is inverse [20] (Figure 2).
Deficit of D hormone is a background factor that lowers ossification and is 
therefore marked as yellow block [21–23]. It is well known that low level of hormone 
D leads to increase in PTH level and lowering of bone mineral density [24]. Presence 
of generalized osteoporosis can additionally intensify this negative trend [25].
4. Bone remodeling (bone turnover) shift
Orthopedic infection and excessive production of pro-inflammatory cytokines 
[15] influence the bone remodeling balance. Such hyperproduction can be triggered 
by infection itself and can increase when the pathogen persists inside the osteo-
blasts. Furthermore, some pathogens can additionally increase the inflammatory 
response because of paracrine action of their factors, interfering with the cytokine 
balance [26]. As it will be shown later, the inflammatory response tends to turn into 
a hyperergic response because of excessive activation of the cell immunity, which is 
an important factor for chronization of the process.
One of the most well-studied bacterial pathogens that is convenient for illustration 
is S. aureus. Many authors [14, 15, 27] show that S. aureus influences both parts of the 
bone turnover-bone resorption and ossification. During infection, S. aureus not only 
destroys (damages) osteoblasts through necrosis and apoptosis, but also lowers their 
proliferation rate. Influence on bone resorption is based on rapid maturation and 
additional activation of the osteoclasts by this pathogen. This mechanism is based 
on excessive synthesis of prostaglandin Е2 (PGE2) by osteoblasts and persisting of 
S. aureus inside the osteoblasts, as well as auto and paracrine regulatory mechanisms 
in which PGE2 plays its biochemical role. The synthesis of osteoprotegerin (OPG) 
is also impaired because of lowering of the level of corresponding mRNA; [28] as a 
result, more RANK-ligand (RANKL) molecules remain unbound and act as osteoclast 
activators. Excessive activation of the osteoclasts and lowering of the number and 
proliferation rate of the osteoblasts lead to obvious shift of the bone turnover to bone 
resorption. As a result, the loss of bone tissue and impairment of its mineralization 
at the site of orthopedic infection (bone infection) can lead to difficulties in bone 
consolidation in patients with bone defects and/or fractures (Figure 3).
“Red blocks” of this part include the OPG and RANK-ligand (RANKL) level 
changes.
“Yellow blocks” include the pre-existing low level of the osteoprotegerin. An 
example is a case of chronic osteomyelitis development in a patient with pre-
existing low-speed bone turnover and associated osteoporosis with OPG synthesis 
impairment.
These markers are rarely used in routine clinical practice but can be of a certain 
value when an appropriate laboratory is available.
Bone Grafts
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OPG is a soluble glycoprotein synthesized by different cell types, including 
osteoblasts [29]. This compound can be found in monomeric (50 kDa) or dimeric 
(120 kDa) form (the dimeric form contains disulfide bonds between monomers). 
Dimeric form has a higher affinity to RANKL than a monomeric one, and the 
chemical analogues of OPG should have the features of dimeric form.
RANKL (RANK-ligand) is a compound synthesized by several cell types. It can 
be expressed in three different molecular forms: transmembrane trimer, primary 
(secreted) form, and cell ectodomain [30]. RANKL serves as a ligand for RANK 
receptor that activates osteoclasts. RANKL is a target for osteoprotegerin; if OPG 
is secreted in low amounts, more RANKL remains unbound and the intensity of 
resorption increases.
Therefore, a “pathogenetic chain” is as follows: infection-osteoblast cell death 
and proliferation rate decrease-OPG synthesis decrease-RANKL inhibition 
decrease-osteoclastogenesis activation-bone resorption increase-shift of bone 
remodeling toward a resorption prevalence-decrease in bone tissue quality and 
quantity in the infection site. The resulting clinical effect is slowing of the consoli-
dation of the bone tissue defects, pseudarthroses, and related conditions.
5. Matrix destruction
The matrix destruction in infection can be explained by several factors. The 
“starting point” in pathogenesis is the infection itself. S. aureus is, as shown by 
Figure 3. 
Pathogenetic stages and processes associated particularly with bone turnover shift.
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several authors [14, 31, 32], capable of persisting in osteoblasts and that leads 
to additional stimulation of inflammatory process that stepwise turns into local 
hyperergic reaction. It is important to take into account that pathogens also play a 
role in matrix destruction—particularly S. aureus can adhere to matrix elements and 
destroy them [33].
The hyperergic reaction leads to excessive synthesis of matrix metalloproteases 
(MMPs). Among them, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) [34] play 
the main role. Excessive synthesis of MMP is a key point in the process because it 
has two major effects:
• Osteoblast cell death and lowering of the proliferation rate; this effect weakens 
the regenerative potential of bone tissue.
• MMPs damage the matrix by themselves, being synthesized in excessive 
amounts [34, 35].
Figure 4. 
Pathogenetic stages and processes associated particularly with bone matrix destruction.
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The matrix destruction leads to increase in following resorption markers: 
B-cross-laps (С-terminal telopeptide) and desoxypyridinoline/creatinine ratio.
• B-cross-laps: This marker is a product of collagen destruction that is a basis of 
bone tissue matrix. B-cross-laps have two octapeptide fragments in structure, 
which are linked with a transverse molecular bond. Its level can be evaluated 
using the immunoassay method [36].
• Increase in the desoxypyridinoline/creatinine ratio: Desoxypyridinoline is a 
molecular basis for transverse bonds between collagen I type molecules in bone 
tissue matrix. Its level increases while the matrix is destroyed. It is important to 
note that this factor can be increased as a result of not only osteoclast activa-
tion, but also of a MMP action.
A clinician should note that the destruction of the matrix is combined with low-
ering of its synthesis by osteoblasts. Therefore, both processes act in a synergic way 
and occur at the same time, which negatively influences the treatment (Figure 4).
6. Background factors
The main background factors that can exacerbate bone tissue metabolism 
impairment at the site of bone infection are: generalized osteoporosis, D-deficit, 
D-insufficiency, and secondary hyperparathyreosis. These factors exacerbate also 
the condition of patients with bone infection, lowering the regenerative potential of 
bone tissue. On the scheme, these factors are marked as yellow blocks.
• The lack of D hormone leads to lowered absorption of calcium in the intestine, 
lowered mineralization of the bone, and consequent decrease of the osteoblast 
function [21–23].
• Secondary hyperparathyreosis: This condition is a result of D-deficit or 
D-insufficiency and is actually a compensative reaction. It has rather complex 
pathogenetic action mechanism [37]. It is shown that during short-term 
increase in PTH level, its influence on bone tissue is anabolic, while during a 
long-term constant increase, its effect becomes catabolic with bone loss as a 
result, for example, at the condition of chronic hormone D-deficit or hormone 
D-insufficiency [37].
Thus, because of the excessive PTH action on bone tissue, two major effects, 
that can be “found out” using markers, occur [38–40]:
• “Mobilization” of calcium and phosphates from the bones.
• Increase in calcium and phosphate levels in the urine because of relatively high 
secreted amounts.
As a result, calcium and phosphates are being literally “washed out” of the 
bone in amounts more than physiological. After that, they are secreted out of 
the organism through urine. A bright example is an increase in vertebral bodies 
fractures risk in patients with primary hyperparathyreosis. Even simple densi-
tometry can help to diagnose the lowered bone density and trabecular thinning. 
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Removal of calcium and phosphates exceeds not only the physiological values or 
amounts, but also the compensative intake with the food leading to progressive 
lowering of bone tissue quality in general and its mineralization in particular. 
To cope successfully with these changes, the secondary parathyreosis should be 
treated and compensative therapy, including calcium, phosphates, and hormone 
D medication, introduced.
7. Summary of scheme review
In this part of the chapter, the etiopathogenetic mechanisms of bone tissue 
metabolism impairment are discussed, as well as reasons for change of laboratory-
measured bone metabolism markers and their levels.
The mentioned markers have a direct link with metabolic impairments of a 
certain type. Such impairments can be found in different diseases, especially in 
patients with chronic osteomyelitis and other forms of bone infection.
The therapy of metabolic bone tissue impairments due to bone (orthopedic) 
infection should combine etiopathogenetic and compensating approaches. For 
example, bisphosphonates can be recommended for use in addition to antibiotic 
therapy and surgery, as well as calcium, D hormone, and other drugs because of the 
bisphosphonates’ ability to decrease the osteoclasts’ activity.
8. Our experience
Nowadays, the published data on epidemiology of metabolic diseases in 
healthy volunteers and orthopedic patients without bone infection (except 
patients with osteoporosis and related diseases) are scarce. Therefore, these data 
cannot serve as statistical material for comparison with data in patients with 
bone infection.
Accordingly, our work is limited to patients with bone infection (chronic osteo-
myelitis and related diseases) already diagnosed. The dynamics of the parameters 
was studied with addition of metabolic disorders therapy and without it.
In 2019, we published a retrospective study; the aim was to evaluate dynamics 
and values of markers and parameters of bone metabolism [16], which included 
112 patients with infected pseudarthroses of long bones (humerus, femur, tibia) 
developing as an exacerbation of chronic osteomyelitis. The study had three main 
purposes:
• Gaining the whole “picture” of metabolic bone tissue disorders in these 
patients.
• Studying the dynamics of corresponding marker level and parameters.
• Comparing the duration of consolidation of pseudarthroses after surgical 
treatment, antibiotic treatment, and using external fixation apparatus (with 
and without bone metabolism correction therapy).
We formed two groups of 56 patients each using anatomical segment-stratified 
randomization. The main group received not only surgery and antibiotic therapy 
but also medication for correction of impaired bone metabolism. The control group 
received the same therapy except correction of bone metabolism.
Bone Grafts
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The dynamics of parameters was evaluated only in the main study group. Data 
from the control group patients were used to evaluate the duration of bone consoli-
dation and comparing them between groups.
To form a “picture” of a bone tissue metabolism, we evaluated the following 
parameters:
• Homeostasis of Ca and P-values: blood Ca, ionized Ca, blood P, PTH, trans-
portation form of D hormone (25(OH)D3).
• Ossification markers: bone alkaline phosphatase, osteocalcin.
• Resorption markers: beta-cross-laps (C-terminal telopeptide).
• Ca and P (daily amount secreted with urine); deoxypyridinoline/creatinine 
ratio.
For therapy, we used calcium medicaments (Ca carbonate, ossein-hydroxyap-
atite complex) and active metabolite of D hormone (alfacalcidol). Dosage was set 
individually for each patient according to a patented way [41] on the basis of the 
following key parameters:
• Sex and age.
• Densitometry results.
• Values of the parameters listed above.
As an anti-resorptive drug, the ibandronate acid was administered (with the 
dosage of 3 mg (3 ml) one time in 3 months).
The described therapy was empirically proved to be effective not only against 
osteoporosis in patients that underwent arthroplasty but also in cases of osteoporo-
sis connected with low intensity of ossification; that was the key reason why it was 
selected for treatment.
The numerical data of patients are described using descriptive statistics. To 
compare the changes in metabolic values after 3 months and before treatment, 
we used the Wilcoxon test. To compare the consolidation duration in main and 
control groups, we used Mann-Whitney U-test. The threshold p-value in all cases 
was set as p < 0.05. The software used was IBM SPSS Statistics 22. All values, 
including theoretically possible outliers, were considered in the statistics (Table 1 
and Figure 5).
Routine screening of the whole population described above exceeds the ranks of 
this study.
We found statistically significant changes after 3 months in osteocalcin level 
(decrease), PTH (decrease), and desoxypyridinoline/creatinine ratio (decrease) 
(respectively: p = 0.043, p = 0.043, p = 0.041). Changes in daily amounts of 
calcium and phosphate secreted with urine, as well as beta-cross-laps were not 
statistically significant but, in our opinion, the follow-up tie of 3 months can be 
insufficient. We suppose that the following mechanisms can take part in forming 
this “picture”:
• Lowering of the resorption because of ibandronic acid use leads to decrease in 
desoxypyridinoline/creatinine ratio.
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• Decrease in osteocalcin level can be explained by lowering of the earlier increased 
(in a compensative way) osteoblast activity that at least partially normalized.
• Decrease of PTH level can be explained by administration of D hormone 
and elimination of D deficit, which also led to decrease in blood calcium. In 
other words, the immediate mechanism of secondary hyperparathyreosis was 
eliminated.
Metabolic marker Value1, 
median ± SD
Range1 Units Test 
p-value2
Threshold 
p-value
Plot3
Са—0 months4 2.4 ± 0.1 2.1–2.71 mmol/l 0.172 0.05 A
Са—3 months5 2.5 ± 0.6 2.38–2.63
Р—0 months 1.2 ± 0.2 0.7–1.6 mmol/l 0.180 B
Р—3 months 1.2 ± 0.147 1.0–1.39
Са2+—0 months 1.2 ± 0.2 0.96–2.2 mmol/l 0.807 C
Са2+—3 months 1.2 ± 0.1 1.11–1.33
Bone alkaline 
phosphatase—0 months
123.5 ± 65.7 60.3–
373.0
U/l 0.893 D
Bone alkaline 
phosphatase—3 months
113.7 ± 24.3 90.0–
148.0
B-cross-laps—0 months 0.7 ± 0.3 0.1–1.1 ng/ml 0.18 E
B-cross-laps—3 months 0.7 ± 0.3 0.2–1.0
Osteocalcin—0 months 22.6 ± 11.1 2.0–46.0 ng/ml 0.043 F
Osteocalcin—3 months 24.9 ± 11.5 11.5–39.0
PTH—0 months 12.5 ± 15.5 1.8–60.0 mol/l 0.043 G
PTH—3 months 2.6 ± 1.0 1.0–4.2
Р (urine, day 
amount)—0 months
24.0 ± 9.6 10.50–
42.5
mmol/day 0.180 H
Р (urine, day 
amount)—3 months
9.9 ± 5.3 3.5–17.1
25-ОН-D3—0 months 17.8 ± 10.2 6.6–40.0 ng/ml 0.715 I
25-ОН-D3—3 months 19.0 ± 10.8 5.0–33.0
Deoxypyridinoline/
creatinine—0 months
11.6 ± 6.4 5.0–38.4 nmol/
mmol Cre
0.041 J
Deoxypyridinoline/
creatinine—3 months
8.6 ± 3.3 3.5–17.5
Са (urine, day 
amount)—0 months
3.7 ± 1.5 1.00–6.34 mmol/day 0.180 K
Са (urine, day 
amount)—3 months
2.5 ± 0.8 1.4–3.6
Data represent the study group (56 patients). Control group is quantitatively equal (56 patients).
1Rounded to first decimal place.
2Wilcoxon signed-rank test. Values are rounded to the third decimal place.
3Letters represent the particular plots at Figure 5A-K for the information to be easily to followed.
40 months—value before operative treatment.
53 months—value at 3 months after the operative treatment.
Statistically significant values (p < 0.05) are labeled as bold.
Table 1. 
Comparative data of patients before and after 3-month therapy of metabolic bone disorders.
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Figure 5. 
(A-K) “Box and whiskers” plots illustrating the data provided in Table 1. Blue box and whiskers (left at 
all figures) represent data of patients before therapy. Orange boxes and whiskers represent data of the same 
patients after 3 months of therapy. A: blood calcium. B: phosphate of the blood. C: ionized calcium, D: bone 
alkaline phosphatase levels, E: beta-cross-laps (C-terminal telopeptide), F: osteocalcin, G: PTH. H: phosphate 
(urine, day amount), I: 25 (OH) D3, J: deoxypyridinoline/creatinine, K: calcium (urine, daily amount). Units: 
see Table 1.
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• Decrease of Ca and phosphates in blood and their daily amounts secreted 
with urine is not statistically significant at 3-month follow-up (р = 0.172 for 
Ca, р = 0.18 for phosphates, р = 0.18 for both daily secreted amounts of Ca 
and phosphates in urine), but we can potentially explain these changes as 
an effect—even statistically insignificant—of PTH level decrease (partial 
normalization).
The rationale of metabolic bone tissue impairment correction is proved by clini-
cal results (decrease of fracture consolidation type in the main group that received 
corresponding therapy). In each group (56 patients), the “anatomical distribution” 
of patients according to a treated segment was as follows:
• Humerus—6 patients
• Femur—25 patients
• Tibia—25 patients
The software used was SPSS Statistics 22. All values, including theoreti-
cally possible outliers, were considered in the statistics. Statistically significant 
changes between groups were found in all studied segments (Table 2 and 
Figure 6).
As shown, the additional therapy of metabolic disorders of bone tissue has a 
statistically significant effect on shortening the duration of bone consolidation in 
patients treated by external fixation apparatus.
In our opinion, the next step should be a comparative analysis of bone metabo-
lism aspects in orthopedic patients with and without bone infection and a study of 
the dynamics of mentioned parameters during a long follow-up period (more than 
3 months).
Anatomical 
segment/study 
group
No. of 
patients
Consolidation 
duration1, days, 
mean ± SD
Range Test 
p-value2
Threshold 
р-value
Plot3
Humerus, main 
group
6 199.9 ± 31.6 147–
243
0.041 0.05 A
Humerus, 
control group
6 254.2 ± 45.1 196–
321
Femur, main 
group
25 266.9 ± 52.7 190–
399
0.009 B
Femur, control 
group
25 338.0 ± 107.1 197–
559
Tibia, main 
group
25 235.0 ± 49.3 154–
351
0.041 C
Tibia, control 
group
25 270.0 ± 61.1 189–
427
Both groups received “standard” surgery and antibiotic therapy.
1Rounded to first decimal place.
2Mann-Whitney U-test. Values are rounded to the third decimal place.
3Letters represent particular plots in Figure 6A–C.
Table 2. 
Comparison of consolidation time in patients with (main group) or without (control group) bone tissue 
metabolism correction therapy.
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9. Conclusion
In this chapter, we attempted to describe the basic pathophysiology of meta-
bolic processes at the site of orthopedic infection. Knowledge of peculiarities of 
such processes is important for an orthopedic surgeon because the general success 
of treatment relies not only on surgery and antibiotic therapy but also etiologic 
therapy of bone metabolism impairment. This thesis is supported not only by 
pathophysiological rationale but also by the results of our study.
Metabolic disorders of bone tissue associated with orthopedic infection are 
complex and yet poorly understood. Research of this topic will improve not only the 
existing treatment strategy but also the philosophy of it and will greatly contribute 
to development of traumatology and orthopedics.
Figure 6. 
(a-c) “Box-and-whiskers” plots illustrating the duration (in days) of bone consolidation in patients that 
underwent treatment of the fractures of different segments exacerbated by orthopedic infection using the 
external fixation apparatus. Left (a): humerus; in the middle (b): femur; right (c): tibia. Blue box and 
whiskers (at the left at all figures) represent data for the main study group that received surgery, antibiotic 
and etiologic metabolism impairment therapy; red box and whiskers (at the right at all figures) represent the 
control group that received surgery and antibiotic therapy, but no treatment of bone metabolism impairment.
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